BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1031 related articles for article (PubMed ID: 18511321)

  • 1. Molecular epidemiology and risk factors of bloodstream infections caused by extended-spectrum beta-lactamase-producing Klebsiella pneumoniae A case-control study.
    Mosqueda-Gómez JL; Montaño-Loza A; Rolón AL; Cervantes C; Bobadilla-del-Valle JM; Silva-Sánchez J; Garza-Ramos U; Villasís-Keever A; Galindo-Fraga A; Palacios GM; Ponce-de-León A; Sifuentes-Osornio J
    Int J Infect Dis; 2008 Nov; 12(6):653-9. PubMed ID: 18511321
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular epidemiology of extended-spectrum beta-lactamase-producing Klebsiella pneumoniae in a neonatal intensive care unit.
    Bagattini M; Crivaro V; Di Popolo A; Gentile F; Scarcella A; Triassi M; Villari P; Zarrilli R
    J Antimicrob Chemother; 2006 May; 57(5):979-82. PubMed ID: 16531430
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An outbreak of hospital-acquired Klebsiella pneumoniae bacteraemia, including strains producing extended-spectrum beta-lactamase.
    Peña C; Pujol M; Ardanuy C; Ricart A; Pallarés R; Liñares J; Ariza J; Gudiol F
    J Hosp Infect; 2001 Jan; 47(1):53-9. PubMed ID: 11161899
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk factors for and outcomes of bloodstream infection caused by extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella species in children.
    Zaoutis TE; Goyal M; Chu JH; Coffin SE; Bell LM; Nachamkin I; McGowan KL; Bilker WB; Lautenbach E
    Pediatrics; 2005 Apr; 115(4):942-9. PubMed ID: 15805368
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epidemiology of an outbreak of antibiotic-resistant Klebsiella pneumoniae at a tertiary care medical center.
    Filozov A; Visintainer P; Carbonaro C; Aguero-Rosenfeld M; Wormser GP; Montecalvo MA
    Am J Infect Control; 2009 Nov; 37(9):723-8. PubMed ID: 19501935
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epidemiology of ciprofloxacin resistance and its relationship to extended-spectrum beta-lactamase production in Klebsiella pneumoniae isolates causing bacteremia.
    Paterson DL; Mulazimoglu L; Casellas JM; Ko WC; Goossens H; Von Gottberg A; Mohapatra S; Trenholme GM; Klugman KP; McCormack JG; Yu VL
    Clin Infect Dis; 2000 Mar; 30(3):473-8. PubMed ID: 10722430
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Extended-spectrum beta-lactamase-producing phenotype signifies a poor prognosis for patients with cefpodoxime-resistant Escherichia coli or Klebsiella pneumoniae bacteremia.
    Lee CI; Lee NY; Yan JJ; Lee HC; Ko NY; Chang CM; Wu CJ; Chen PL; Wang LR; Ko WC
    J Microbiol Immunol Infect; 2009 Aug; 42(4):303-9. PubMed ID: 19949753
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epidemiology and clinical features of bloodstream infections caused by AmpC-type-beta-lactamase-producing Klebsiella pneumoniae.
    Pai H; Kang CI; Byeon JH; Lee KD; Park WB; Kim HB; Kim EC; Oh MD; Choe KW
    Antimicrob Agents Chemother; 2004 Oct; 48(10):3720-8. PubMed ID: 15388426
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Extended-spectrum beta-lactamase-producing Klebsiella pneumoniae in paediatric wards: a nested case-control study.
    Demir S; Soysal A; Bakir M; Kaufmann ME; Yagci A
    J Paediatr Child Health; 2008 Oct; 44(10):548-53. PubMed ID: 18557808
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An outbreak of infection due to beta-Lactamase Klebsiella pneumoniae Carbapenemase 2-producing K. pneumoniae in a Greek University Hospital: molecular characterization, epidemiology, and outcomes.
    Souli M; Galani I; Antoniadou A; Papadomichelakis E; Poulakou G; Panagea T; Vourli S; Zerva L; Armaganidis A; Kanellakopoulou K; Giamarellou H
    Clin Infect Dis; 2010 Feb; 50(3):364-73. PubMed ID: 20041768
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bloodstream infections due to extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae: risk factors for mortality and treatment outcome, with special emphasis on antimicrobial therapy.
    Kang CI; Kim SH; Park WB; Lee KD; Kim HB; Kim EC; Oh MD; Choe KW
    Antimicrob Agents Chemother; 2004 Dec; 48(12):4574-81. PubMed ID: 15561828
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular epidemiology and antimicrobial susceptibility of extended- and broad-spectrum beta-lactamase-producing Klebsiella pneumoniae isolated in Portugal.
    Mendonça N; Ferreira E; Louro D; ; Caniça M
    Int J Antimicrob Agents; 2009 Jul; 34(1):29-37. PubMed ID: 19272757
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of ESBL-producing Klebsiella pneumoniae bacteraemia with carbapenems or flomoxef: a retrospective study and laboratory analysis of the isolates.
    Lee CH; Su LH; Tang YF; Liu JW
    J Antimicrob Chemother; 2006 Nov; 58(5):1074-7. PubMed ID: 16971415
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Laboratory identification, risk factors, and clinical outcomes of patients with bacteremia due to Escherichia coli and Klebsiella pneumoniae producing extended-spectrum and AmpC type β-lactamases.
    Tsui K; Wong SS; Lin LC; Tsai CR; Chen LC; Huang CH
    J Microbiol Immunol Infect; 2012 Jun; 45(3):193-9. PubMed ID: 22580086
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Extended-spectrum beta-lactamase-producing Klebsiella pneumoniae hospital acquired bacteremia. Risk factors and clinical outcome.
    Panhotra BR; Saxena AK; Al-Ghamdi AM
    Saudi Med J; 2004 Dec; 25(12):1871-6. PubMed ID: 15711657
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of risk factors for the acquisition of bloodstream infections with extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella species in the intensive care unit; antibiotic management and clinical outcome.
    Cordery RJ; Roberts CH; Cooper SJ; Bellinghan G; Shetty N
    J Hosp Infect; 2008 Feb; 68(2):108-15. PubMed ID: 18063198
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bacteraemia due to extended-spectrum beta-lactamase-producing Escherichia coli (ESBL-EC) in cancer patients: clinical features, risk factors, molecular epidemiology and outcome.
    Gudiol C; Calatayud L; Garcia-Vidal C; Lora-Tamayo J; Cisnal M; Duarte R; Arnan M; Marin M; Carratalà J; Gudiol F
    J Antimicrob Chemother; 2010 Feb; 65(2):333-41. PubMed ID: 19959544
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of control group selection in the analysis of risk factors for extended spectrum beta-lactamase-producing Klebsiella pneumoniae infections. A prospective controlled study.
    Behar PR; Teixeira PJ; Fachel JM; Kalil AC
    J Hosp Infect; 2008 Feb; 68(2):123-9. PubMed ID: 18192077
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expansion and countrywide dissemination of ST11, ST15 and ST147 ciprofloxacin-resistant CTX-M-15-type beta-lactamase-producing Klebsiella pneumoniae epidemic clones in Hungary in 2005--the new 'MRSAs'?
    Damjanova I; Tóth A; Pászti J; Hajbel-Vékony G; Jakab M; Berta J; Milch H; Füzi M
    J Antimicrob Chemother; 2008 Nov; 62(5):978-85. PubMed ID: 18667450
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Extended-spectrum beta-lactamase in Klebsiella pneumoniae and Escherichia coli isolates].
    Xiong Z; Zhu D; Zhang Y; Wang F
    Zhonghua Yi Xue Za Zhi; 2002 Nov; 82(21):1476-9. PubMed ID: 12509910
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 52.